Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …

In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune
effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 …

Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …

The infusion of chimaeric antigen receptor (CAR) T cells can trigger the release of life-
threatening supraphysiological levels of pro-inflammatory cytokines. However, uncertainty …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Chimeric antigen receptor T cell (CAR-T) therapies, including axicabtagene ciloleucel (axi-
cel) and tisagenlecleucel (tisa-cel), are innovative treatments for patients with relapsed or …

Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be
considered ineligible for curative-intent therapy including high-dose chemotherapy with …

Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various
hematological malignancies. However, its application in solid tumors is still limited. Clinical …